@article{Lamberti2020,

title = {Drug Delivery of siRNA Therapeutics},

author = {Gaetano Lamberti and Anna Angela Barba},

url = {https://www.mdpi.com/1999-4923/12/2/178/pdf},

doi = {10.3390/pharmaceutics12020178},

year  = {2020},

date = {2020-02-20},

journal = {Pharmaceutics},

volume = {12(2)},

number = {178},

keywords = {aptamers, Drug Delivery Systems, gene therapy, liposomes, nanoparticles, polycations, siRNA},

pubstate = {published},

tppubtype = {article}

}

@article{Barba2019,

title = {Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications},

author = {Anna Angela Barba and Sabrina Bochicchio and Annalisa Dalmoro and Gaetano Lamberti},

url = {https://www.mdpi.com/1999-4923/11/8/360},

doi = {10.3390/pharmaceutics11080360},

year  = {2019},

date = {2019-07-24},

journal = {Pharmaceutics},

volume = {11},

number = {360},

abstract = {In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in gene therapy has had a great impact in the medical field, holding enormous promise, becoming “the latest generation medicine” with the first ever siRNA-lipid based formulation approved by the United States Food and Drug Administration (FDA) for human use, and currently on the market under the trade name Onpattro™. The growth of such powerful biologic therapeutics has gone hand in hand with the progress in delivery systems technology, which is absolutely required to improve their safety and effectiveness. Lipid carrier systems, particularly liposomes, have been proven to be the most suitable vehicles meeting NABDs requirements in the medical healthcare framework, limiting their toxicity, and ensuring their delivery and expression into the target tissues. In this review, after a description of the several kinds of liposomes structures and formulations used for in vitro or in vivo NABDs delivery, the broad range of siRNA-liposomes production techniques are discussed in the light of the latest technological progresses. Then, the current status of siRNA-lipid delivery systems in clinical trials is addressed, offering an updated overview on the clinical goals and the next challenges of this new class of therapeutics which will soon replace traditional drugs},

keywords = {clinical trials, liposomes, Micro and Nano Vectors, NABDs, siRNA},

pubstate = {published},

tppubtype = {article}

}

@article{Bochicchio2014,

title = {Liposomes as siRNA Delivery Vectors},

author = {Sabrina Bochicchio and Annalisa Dalmoro and Anna Angela Barba and Gabriele Grassi and Gaetano Lamberti},

url = {http://www.eurekaselect.com/128256/article},

doi = {10.2174/1389200216666150206124913},

issn = {1389-2002},

year  = {2014},

date = {2014-01-01},

journal = {Current drug metabolism},

volume = {15},

number = {9},

pages = {882--892},

publisher = {Bentham Science Publishers},

abstract = {Nucleic Acid Based Drugs (NABDs) constitute a class of promising and powerful therapeutic new agents with limited side effects, potentially useable against a wide range of diseases, including cancer. Among them, the short interfering RNAs (siRNAs), represent very effective molecules. Despite their in vitro efficacy, the major drawback that limits siRNAs usage consists in a difficult delivery due to their very low stability in physiological fluids, and to their limited membrane-permeability through physiological barriers. On the other hand, the liposomes (lipid bilayers closed in vesicles of various sizes) represent interesting drug delivery systems (DDSs) which can be tailored in order to get the best performance in terms of load, vesicle size and transfection yield. In this work, the current state of study in these two fields, and the connections between them, are briefly summarized.},

keywords = {Drug Delivery Systems, liposome, Micro and Nano Vectors, siRNA},

pubstate = {published},

tppubtype = {article}

}